Corcept Therapeutics Incorporated (CORT) — Financial statements
Income statement, balance sheet, and cash flow for Corcept Therapeutics Incorporated — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 761↑12.8% | 675↑39.9% | 482↑20.0% | 402↑9.8% | 366 | |
| Cost of Revenue | 13↑19.3% | 11↑67.9% | 6↑20.4% | 5↑2.0% | 5 | |
| Gross Profit | 748↑12.7% | 664↑39.6% | 476↑20.0% | 396↑9.9% | 361 | |
| Operating Expenses | ||||||
| R&D Expenses | 255↑3.2% | 247↑33.9% | 184↑40.7% | 131↑15.0% | 114 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 449↑60.1% | 280↑52.1% | 184↑20.6% | 153↑24.9% | 122 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 704↑33.5% | 527↑43.0% | 369↑29.9% | 284↑20.2% | 236 | |
| Total Costs & Expenses | 717↑33.2% | 538↑43.5% | 375↑29.7% | 289↑19.8% | 242 | |
| Operating Results | ||||||
| Operating Income | 45↓67.3% | 137↑27.7% | 107↓4.8% | 113↓9.5% | 124 | |
| Depreciation & Amortization | 2↑41.5% | 1↑28.2% | 1↓17.2% | 1↓59.0% | 3 | |
| EBITDA | 47↓66.2% | 138↑27.7% | 108↓4.9% | 114↓11.0% | 128 | |
| EBIT | 45↓67.3% | 137↑27.7% | 107↓4.8% | 113↓9.9% | 125 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 25↑42.1% | 17↑385.7% | 4↑572.4% | 0.53 | |
| Interest Income | 0.00↓100.0% | 25↑42.1% | 17↑385.7% | 4↑572.4% | 0.53 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.53 | |
| Other Income / Expenses | 22↓11.7% | 25↑42.1% | 17↑385.7% | 4↑572.4% | 0.53 | |
| Income Before Tax | 66↓58.8% | 161↑29.7% | 125↑7.2% | 116↓7.1% | 125 | |
| Income Tax Expense | -33↓263.6% | 20↑10.1% | 18↑24.7% | 15↑18.2% | 12 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 100↓29.4% | 141↑33.0% | 106↑4.7% | 101↓9.9% | 113 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 100↓28.7% | 140↑31.6% | 106↑4.7% | 101↓9.9% | 113 | |
| Bottom-Line Net Income | 98↓29.7% | 140↑32.5% | 105↑4.2% | 101↓10.0% | 113 | |
| EPS (Basic) | 0.95↓29.6% | 1.35↑32.4% | 1.02↑7.4% | 0.95↓2.1% | 0.97 | |
| EPS (Diluted) | 0.82↓33.3% | 1.23↑30.9% | 0.94↑8.0% | 0.87↓2.2% | 0.89 | |
| Weighted Average Shares | 104↑0.6% | 103↓0.3% | 104↓3.0% | 107↓7.7% | 116 | |
| Weighted Average Diluted Shares | 120↑5.7% | 113↑1.6% | 112↓3.6% | 116↓7.9% | 126 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.